Luminary Group’s Post

𝗟𝘂𝗺𝗶𝗻𝗮𝗿𝘆 𝗚𝗿𝗼𝘂𝗽, 𝗚𝗹𝗼𝗯𝗮𝗹 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗖𝗼𝗻𝘀𝘂𝗹𝘁𝗮𝗻𝗰𝘆 #artificialintelligence #realworlddata #mergersandacquisitions #realworldevidence #productlifecycle #regulatory #pharmacovigilence #bioprocessing #cdmo #clinicaltrials #consultancy #eclinical #saas #ecoa

𝗜𝗱𝗲𝗮𝘆𝗮 𝘀𝗵𝗼𝘄𝗰𝗮𝘀𝗲𝘀 𝗽𝗿𝗼𝗼𝗳-𝗼𝗳-𝗰𝗼𝗻𝗰𝗲𝗽𝘁 𝗱𝗮𝘁𝗮 𝗶𝗻 𝗮 𝗯𝗼𝗼𝘀𝘁 𝘁𝗼 𝘀𝘆𝗻𝘁𝗵𝗲𝘁𝗶𝗰 𝗹𝗲𝘁𝗵𝗮𝗹𝗶𝘁𝘆 𝗽𝗹𝗮𝘆 Fresh Phase 2 data are adding weight to Ideaya IDEAYA Biosciences case for a targeted therapy it believes could be a first-in-class treatment option for certain …Yujiro S. H. https://lnkd.in/d-wViywi

𝗖𝗶𝗿𝗰𝗹𝗲 𝗣𝗵𝗮𝗿𝗺𝗮 𝗿𝗮𝗶𝘀𝗲𝘀 $𝟱𝟰𝗠 𝗮𝘀 𝗽𝗮𝗿𝘁 𝗼𝗳 𝗦𝗲𝗿𝗶𝗲𝘀 𝗗 𝘄𝗵𝗶𝗹𝗲 𝗺𝗮𝗰𝗿𝗼𝗰𝘆𝗰𝗹𝗲𝘀 𝗵𝗲𝗮𝘁 𝘂𝗽 Circle Pharma, Inc. a startup working on macrocycles for the “undruggable,” is seeking about $117 million for a Series D. The company recently closed the first …David J. Earp, JD, PhD https://lnkd.in/dBk_adUB

𝗦𝗲𝗻𝗶𝗼𝗿 𝗧𝗮𝗹𝗲𝗻𝘁 𝗦𝗵𝗶𝗳𝘁 𝗤𝟮 𝟮𝟬𝟮𝟰 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 In Q2 2024, there have been notable senior-level changes across the Real World Evidence, Digital Health, Consulting, and CDMO sectors. These shifts reflect the industry's ongoing evolution and the increasing demand for leaders with expertise in business transformation, strategic change, and entrepreneurial drive. In the Real World Evidence sector, new senior leaders have been appointed to spearhead efforts in leveraging real-world data for enhanced clinical and commercial insights. These changes aim to strengthen capabilities in generating robust evidence to support regulatory submissions and market access strategies in a highly competitive field, marked by fierce competition from both large corporations and smaller enterprises. 𝗨𝗦𝗔 Kyle Armbrester - CEO at Datavant Brett Kleger - CEO at Inspire Rachael Thomas Higgins - CCO at PicnicHealth Jade Cusick - CCO at Ontada Ben Stormer - CCO at Annexus Health Ryan Sloan - CGO at Galileo Jennifer M. - CGO at Lightship Lindsay Daniel - CHRO at YPrime Joshua Max Davis - SVP Commercial Operations at Ada Health Amy Eaves - BU Head Healthcare & Life Sciences at Synoptek 𝗘𝘂𝗿𝗼𝗽𝗲 Marc Funk - CEO at MARBIO Abdelaziz Toumi, PhD, MBA - CEO at Lupin Jonathan Burr - CCO at Cytel Martin Keil - VP & GM at Revvity Roberto Ascione - President at EVERSANA Pamela V. - VP HEOR, Value & Evidence at EVERSANA Jean-Christophe Massot - VP Information & Communications ProductLife Group Frédéric GAUSSENS - VP Europe & APAC PharmaLex We are excited to see how Q3 unfolds with any future senior talent shifts. If you are seeking senior-level opportunities or looking to attract senior talent, please contact our executive search team at Luminary Group. Stay tuned for the next series! #realworldevidence #rwe #rwd #regulatoryaffairs #cdmo #pharmaceutical #biotechnology

𝗝&𝗝 𝗮𝗻𝗱 𝗟𝗲𝗴𝗲𝗻𝗱 𝘀𝗮𝘆 𝗖𝗮𝗿𝘃𝘆𝗸𝘁𝗶 𝗶𝗺𝗽𝗿𝗼𝘃𝗲𝗱 𝘀𝘂𝗿𝘃𝗶𝘃𝗮𝗹 𝗶𝗻 𝗲𝗮𝗿𝗹𝗶𝗲𝗿-𝗹𝗶𝗻𝗲 𝗺𝘂𝗹𝘁𝗶𝗽𝗹𝗲 𝗺𝘆𝗲𝗹𝗼𝗺𝗮 In a late-stage study, Johnson & Johnson and Legend Biotech CAR-T therapy Carvykti improved survival in multiple myeloma patients who had received one to three … https://lnkd.in/dfUE5XyR

𝗗𝘂𝗽𝗶𝘅𝗲𝗻𝘁 𝘄𝗶𝗻𝘀 𝗘𝗨 𝗹𝗮𝗯𝗲𝗹 𝗲𝘅𝗽𝗮𝗻𝘀𝗶𝗼𝗻 𝗶𝗻 𝗖𝗢𝗣𝗗 𝗮𝗵𝗲𝗮𝗱 𝗼𝗳 𝗱𝗲𝗹𝗮𝘆𝗲𝗱 𝗙𝗗𝗔 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻 Sanofi and Regeneron Therapeutics INC DUPIXENT® (dupilumab) HCP has notched another indication in the EU, this time for a common lung disease, marking the first-ever targeted therapy for the … https://lnkd.in/dsuPtPe2

𝗕𝗶𝗼𝗴𝗲𝗻 𝗶𝘀 𝗽𝘂𝗿𝘀𝘂𝗶𝗻𝗴 𝗺𝗼𝗿𝗲 𝗱𝗲𝗮𝗹𝗺𝗮𝗸𝗶𝗻𝗴 𝘁𝗵𝗶𝘀 𝘆𝗲𝗮𝗿, 𝘄𝗶𝘁𝗵 𝗽𝗹𝗮𝗻𝘀 𝘁𝗼 𝘀��𝗲𝗻𝗱 𝘂𝗽 𝘁𝗼 $𝟴𝗕 Biogen appears to be subtly signaling it has a larger appetite for M&A than previously stated. Adam Keeney PhD https://lnkd.in/dim-XMyW

𝗠𝗼𝗱𝗲𝗿𝗻𝗮 𝘄𝗶𝗻𝘀 $𝟭𝟳𝟲𝗠 𝗕𝗔𝗥𝗗𝗔 𝗮𝘄𝗮𝗿𝗱 𝘁𝗼 𝗳𝗶𝗻𝗮𝗻𝗰𝗲 𝗯𝗶𝗿𝗱 𝗳𝗹𝘂 𝘄𝗼𝗿𝗸 Moderna received a significant boost from the federal government, snagging a $176 million contract to help advance a bird flu vaccine. The award, which was … https://lnkd.in/ddasMenm

𝗜𝗻 𝗯𝗶𝗼𝘁𝗲𝗰𝗵'𝘀 𝘂𝗻𝗲𝘃𝗲𝗻 𝗿𝗲𝗰𝗼𝘃𝗲𝗿𝘆, 𝟱𝟬 𝘀𝘁𝗮𝗿𝘁𝘂𝗽𝘀 𝗿𝗮𝗶𝘀𝗲𝗱 𝗺𝗲𝗴𝗮𝗿𝗼𝘂𝗻𝗱𝘀 𝗶𝗻 𝗳𝗶𝗿𝘀𝘁 𝗵𝗮𝗹𝗳 𝗼𝗳 𝟮𝟬𝟮𝟰 The list of nine-figure financings for private biotechs is starting to look like the scrolling receipts from CVS or Walgreens If that pace continues, it … https://lnkd.in/dvVXbFfg